BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 29513759)

  • 41. Relationship between the expression of CD25 and CD69 on the surface of lymphocytes T and B from peripheral blood and bone marrow of patients with chronic lymphocytic leukemia and established prognostic factors of this disease.
    Grywalska E; Bartkowiak-Emeryk M; Pasiarski M; Olszewska-Bożek K; Mielnik M; Podgajna M; Pieczykolan M; Hymos A; Fitas E; Surdacka A; Góźdź S; Roliński J
    Adv Clin Exp Med; 2018 Jul; 27(7):987-999. PubMed ID: 29893517
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Redefining the prognostic likelihood of chronic lymphocytic leukaemia patients with borderline percentage of immunoglobulin variable heavy chain region mutations.
    Raponi S; Ilari C; Della Starza I; Cappelli LV; Cafforio L; Piciocchi A; Arena V; Mariglia P; Mauro FR; Gentile M; Cutrona G; Moia R; Favini C; Morabito F; Rossi D; Gaidano G; Guarini A; Del Giudice I; Foà R
    Br J Haematol; 2020 Jun; 189(5):853-859. PubMed ID: 32064595
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The prognostic role of CXCR3 expression by chronic lymphocytic leukemia B cells.
    Ocaña E; Delgado-Pérez L; Campos-Caro A; Muñóz J; Paz A; Franco R; Brieva JA
    Haematologica; 2007 Mar; 92(3):349-56. PubMed ID: 17339184
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prognostic effect of Ki-67 expression in rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone-treated diffuse large B-cell lymphoma is limited to non-germinal center B-cell-like subtype in late-elderly patients.
    Koh YW; Hwang HS; Park CS; Yoon DH; Suh C; Huh J
    Leuk Lymphoma; 2015; 56(9):2630-6. PubMed ID: 25573205
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Clinical efficacy and safety of chemoimmunotherapy with rituximab,fludarabine and cyclophosphamide for chronic lymphocytic leukemia].
    Li F; Yi SH; Yu Z; Xing LJ; Xu Y; Qi JY; Zhao YZ; Li ZJ; Qiu LG
    Zhonghua Xue Ye Xue Za Zhi; 2013 May; 34(5):383-8. PubMed ID: 23688746
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical significance of DNA methylation in chronic lymphocytic leukemia patients: results from 3 UK clinical trials.
    Wojdacz TK; Amarasinghe HE; Kadalayil L; Beattie A; Forster J; Blakemore SJ; Parker H; Bryant D; Larrayoz M; Clifford R; Robbe P; Davis ZA; Else M; Howard DR; Stamatopoulos B; Steele AJ; Rosenquist R; Collins A; Pettitt AR; Hillmen P; Plass C; Schuh A; Catovsky D; Oscier DG; Rose-Zerilli MJJ; Oakes CC; Strefford JC
    Blood Adv; 2019 Aug; 3(16):2474-2481. PubMed ID: 31434681
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Evaluation of trisomy 12 by fluorescence in situ hybridization in peripheral blood, bone marrow and lymph nodes of patients with B-cell chronic lymphocytic leukemia.
    Liso V; Capalbo S; Lapietra A; Pavone V; Guarini A; Specchia G
    Haematologica; 1999 Mar; 84(3):212-7. PubMed ID: 10189384
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Chronic Lymphocytic Leukemia B-Cell Normal Cellular Counterpart: Clues From a Functional Perspective.
    Darwiche W; Gubler B; Marolleau JP; Ghamlouch H
    Front Immunol; 2018; 9():683. PubMed ID: 29670635
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Increased IL-10/IL-17 ratio is aggravated along with the prognosis of patients with chronic lymphocytic leukemia.
    Pang N; Zhang R; Li J; Zhang Z; Yuan H; Chen G; Zhao F; Wang L; Cao H; Qu J; Ding J
    Int Immunopharmacol; 2016 Nov; 40():57-64. PubMed ID: 27584054
    [TBL] [Abstract][Full Text] [Related]  

  • 50. 17p deletion strongly influences rituximab elimination in chronic lymphocytic leukemia.
    Bagacean C; Tempescul A; Ternant D; Banet A; Douet-Guilbert N; Bordron A; Bendaoud B; Saad H; Zdrenghea M; Berthou C; Paintaud G; Renaudineau Y
    J Immunother Cancer; 2019 Jan; 7(1):22. PubMed ID: 30696487
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Gain of the short arm of chromosome 2 (2p gain) has a significant role in drug-resistant chronic lymphocytic leukemia.
    Kostopoulou F; Gabillaud C; Chapiro E; Grange B; Tran J; Bouzy S; Degaud M; Ghamlouch H; Le Garff-Tavernier M; Maloum K; Choquet S; Leblond V; Gabarre J; Lavaud A; Morel V; Roos-Weil D; Uzunov M; Guieze R; Bernard OA; Susin SA; Tournilhac O; Nguyen-Khac F;
    Cancer Med; 2019 Jun; 8(6):3131-3141. PubMed ID: 31066214
    [TBL] [Abstract][Full Text] [Related]  

  • 52. CD69 expression potentially predicts response to bendamustine and its modulation by ibrutinib or idelalisib enhances cytotoxic effect in chronic lymphocytic leukemia.
    Montraveta A; Lee-Vergés E; Roldán J; Jiménez L; Cabezas S; Clot G; Pinyol M; Xargay-Torrent S; Rosich L; Arimany-Nardí C; Aymerich M; Villamor N; López-Guillermo A; Pérez-Galán P; Roué G; Pastor-Anglada M; Campo E; López-Guerra M; Colomer D
    Oncotarget; 2016 Feb; 7(5):5507-20. PubMed ID: 26701728
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Association between molecular lesions and specific B-cell receptor subsets in chronic lymphocytic leukemia.
    Rossi D; Spina V; Bomben R; Rasi S; Dal-Bo M; Bruscaggin A; Rossi FM; Monti S; Degan M; Ciardullo C; Serra R; Zucchetto A; Nomdedeu J; Bulian P; Grossi A; Zaja F; Pozzato G; Laurenti L; Efremov DG; Di-Raimondo F; Marasca R; Forconi F; Del Poeta G; Gaidano G; Gattei V
    Blood; 2013 Jun; 121(24):4902-5. PubMed ID: 23637131
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Persistently low lymphocyte counts after FCR therapy for chronic lymphocytic leukemia are associated with longer overall survival.
    Joffe E; Ariela Arad N; Bairey O; Fineman R; Ruchlemer R; Rahimi-Levene N; Shvidel L; Greenbaum U; Aviv A; Tadmor T; Braester A; Goldschmidt N; Polliack A; Herishanu Y
    Hematol Oncol; 2018 Feb; 36(1):128-135. PubMed ID: 28639416
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Telomere length and telomerase levels delineate subgroups of B-cell chronic lymphocytic leukemia with different biological characteristics and clinical outcomes.
    Rampazzo E; Bonaldi L; Trentin L; Visco C; Keppel S; Giunco S; Frezzato F; Facco M; Novella E; Giaretta I; Del Bianco P; Semenzato G; De Rossi A
    Haematologica; 2012 Jan; 97(1):56-63. PubMed ID: 21933855
    [TBL] [Abstract][Full Text] [Related]  

  • 56. RelB, together with RelA, sustains cell survival and confers proteasome inhibitor sensitivity of chronic lymphocytic leukemia cells from bone marrow.
    Xu J; Zhou P; Wang W; Sun A; Guo F
    J Mol Med (Berl); 2014 Jan; 92(1):77-92. PubMed ID: 24042463
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Time-to-progression after front-line fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy for chronic lymphocytic leukaemia: a retrospective, multicohort study.
    Herling CD; Coombes KR; Benner A; Bloehdorn J; Barron LL; Abrams ZB; Majewski T; Bondaruk JE; Bahlo J; Fischer K; Hallek M; Stilgenbauer S; Czerniak BA; Oakes CC; Ferrajoli A; Keating MJ; Abruzzo LV
    Lancet Oncol; 2019 Nov; 20(11):1576-1586. PubMed ID: 31582354
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A single-institution retrospective cohort study of first-line R-EPOCH chemoimmunotherapy for Richter syndrome demonstrating complex chronic lymphocytic leukaemia karyotype as an adverse prognostic factor.
    Rogers KA; Huang Y; Ruppert AS; Salem G; Stephens DM; Heerema NA; Andritsos LA; Awan FT; Byrd JC; Flynn JM; Maddocks KJ; Jones JA
    Br J Haematol; 2018 Jan; 180(2):259-266. PubMed ID: 29193006
    [TBL] [Abstract][Full Text] [Related]  

  • 59. In B-cell chronic lymphocytic leukaemia chromosome 17 abnormalities and not trisomy 12 are the single most important cytogenetic abnormalities for the prognosis: a cytogenetic and immunophenotypic study of 480 unselected newly diagnosed patients.
    Geisler CH; Philip P; Christensen BE; Hou-Jensen K; Pedersen NT; Jensen OM; Thorling K; Andersen E; Birgens HS; Drivsholm A; Ellegaard J; Larsen JK; Plesner T; Brown P; Andersen PK; Hansen MM
    Leuk Res; 1997; 21(11-12):1011-23. PubMed ID: 9444933
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prognostic relevance of the FAB morphological criteria in chronic lymphocytic leukemia: correlations with IgVH gene mutational status and other prognostic markers.
    Schwarz J; Mikulenková D; Cermáková M; Polanská V; Michalová K; Marinov I; Campr V; Ransdorfová S; Marková J; Pavlistová L; Brezinová J; Sajdová J; Sponerová D; Volková Z; Benesová K; Cermák J; Vítek A; Cetkovský P
    Neoplasma; 2006; 53(3):219-25. PubMed ID: 16652191
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.